05/20/2025

Patient Access to Cancer Care at Risk Under International Drug Pricing Proposal

On May 12, President Trump signed an executive order (EO) directing the administration to communicate most-favored-nation (MFN) drug price targets to pharmaceutical manufacturers for sales in the United States. If “significant progress” is not delivered in meeting MFN price targets within 30 days, the administration will propose rulemaking to impose a MFN drug pricing plan.

The Association for Clinical Oncology (ASCO) strongly opposed an earlier effort to establish a MFN drug pricing model in Medicare, since it would have imposed a nationwide, mandatory payment model on cancer care that tied Medicare drug reimbursement to drug prices abroad—without any evidence that doing so would lower costs without also harming Medicare beneficiaries.

READ MORE